TQB3205 capsules for adults with advanced malignant tumors.
Official title: Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07482592 · Data updated 2026-11-12
TQB3205 capsules will be tested for safety, tolerability, and how the drug is processed in the body in adults with advanced malignant tumors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 156 (estimated) |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Industry-sponsored |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Status | Recruiting |
| Started | April 15, 2026 |
| Main results expected | December 2027 |
| Study ends | December 2028 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT07482592 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with advanced malignant tumors, ECOG performance status 0–1, at least one measurable lesion, adequate organ function, and expected survival of at least three months are the intended participants.
✕Probably not a fit
Patients with poor performance status, significant organ dysfunction, very limited life expectancy, recent major surgery, or who are pregnant are unlikely to be eligible or to receive benefit from this phase 1 safety-focused trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a phase 1, single-center, open-label, non-randomized, single-arm trial using dose-escalation and dose-expansion cohorts to study oral TQB3205 capsules. The trial includes single-dose and continuous-dosing schedules to characterize safety, tolerability, and pharmacokinetics, with preliminary measures of antitumor activity. Eligible participants are adults with advanced malignant tumors, ECOG 0-1, measurable disease, and adequate organ function. Study visits and dosing occur at Tianjin Medical University Cancer Institute & Hospital.
Why it matters
Potential benefit: If successful, TQB3205 could become a new oral treatment option that may slow tumor growth or offer clinical benefit for some people with advanced cancers.
How similar studies have gone: This is an early-phase first-in-human design; while some novel oral anticancer agents have advanced from phase 1 to later success, many early-phase agents do not demonstrate later clinical benefit.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects voluntarily joined the study, signed informed consent form, and with good compliance. * ≥18 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-1; at least 3 months expected survival period. * At least 1 measurable lesion for efficacy evaluation. * The function of main organs is normal. * Women of childbearing age should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study, and have a negative serum or urine pregnancy test within 7 days before enrollment in the study; Men should agree to use effective contraceptive measures during the study period and within 6 months after the end of the study period. Exclusion Criteria: * Individuals who have undergone major surgical treatment, significant traumatic injury, or major surgery during the expected study treatment period within 4 weeks prior to the first medication (excluding surgeries specified in the protocol), or have long-term untreated wounds or fractures. (Major surgery is defined as surgery at level 3 or above in the National Surgical Classification Catalogue 2022 edition); * Subjects who experience any bleeding or bleeding events ≥ CTC AE grade 3 within 4 weeks prior to the first administration. * Active syphilis infected individuals in need of treatment * Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders; * Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation; * History of hepatic encephalopathy; * Active or uncontrolled infections (≥ CTC AE level 2 infection); * Patients with renal failure requiring hemodialysis or peritoneal dialysis; * History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases; * Individuals with epilepsy who require treatment; * Poor control of diabetes (assessed by the investigator); * Known to be allergic to research drugs or excipients; * Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first medication; * According to the researcher's judgment, there is a situation that seriously endangers the safety of the subjects or affects their ability to complete the study.
Where it's running
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Jihui Hao, Doctor
- Email: haojihui@tjmuch.com
- Phone: 022-23340123-3070
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TQB3019 capsules for adults with advanced malignant tumors — safety and early effects
This phase 1 trial will test whether TQB3019 capsules are safe and show early signs of benefit in adults with advanced malignant tumors.
-
TQF3250 Capsules in overweight and obese adults with limited weight loss from lifestyle changes
This phase 1b study tests whether TQF3250 capsules are safe and tolerable, and whether they show preliminary signs of benefit, in adults with overweight or obesity who have not achieved enough weight loss with simple lifestyle changes.
-
TQF3250 capsules for adults with type 2 diabetes and overweight/obesity
A small, early-phase study will test the safety and how the body handles different doses of TQF3250 pills in adults with type 2 diabetes who are overweight or obese.
-
GPC3-targeted ADC for advanced solid tumors
This early-phase trial tests a Glypican-3 targeted antibody-drug conjugate (TQB6426) in adults with advanced cancers to see if it is safe and tolerable and to explore potential anti-tumor activity.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
TQB3126 in Breast Cancer: Safety, PK, and Early Efficacy in Adults
This study tests TQB3126 to see if it is safe and tolerable and to get early signals of benefit in adults with breast cancer who have progressed after prior therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.